RT Book, Section
A1 Dietrich, Eric
A2 Whalen, Karen
A2 Hardin, Heather C.
SR Print(0)
ID 1150201320
T1 Osteoarthritis MTM Data Set
T2 Medication Therapy Management: A Comprehensive Approach, 2e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9781260108453
LK accesspharmacy.mhmedical.com/content.aspx?aid=1150201320
RD 2022/07/01
AB KEY  POINTSTreatment  goals  for  osteoarthritis  (OA)  should  be  identified  prior  to  beginning  treatment  and  should  be  individualized  on  a  patient-by-patient  basis.  An  acceptable  balance  between  minimizing  pain  and  side  effects,  while  maximizing  functionality  and  quality  of  life,  should  be  targeted.Optimal  treatment  of  OA  includes  both  pharmacologic  and  nonpharmacologic  therapies.  Adherence  to  nonpharmacologic  treatment  should  be  assessed  at  each  medication  therapy  management  (MTM)  encounter.Given  the  significant  adverse  effects  of  chronic  treatment  with  nonsteroidal  anti-inflammatory  drugs  (NSAIDs),  reassessment  of  risk  factors  such  as  cardiovascular  risk  and  risk  of  gastrointestinal  bleeding  should  be  conducted  during  each  MTM  encounter  to  ensure  safety  of  continued  treatment  and  potential  need  for  additional  medications  to  reduce  risk  (eg,  proton-pump  inhibitors  for  risk  of  gastrointestinal  bleeding).Assessment  of  potential  adverse  effects  from  analgesic  therapy  should  be  determined  during  each  MTM  encounter.  Importantly,  bleeding  from  NSAIDs  or  constipation,  sedation,  and/or  respiratory  depression  associated  with  opioids  should  be  monitored  frequently.